Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104455 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL64957 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829630 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9720673 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829291 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829172 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL829553 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL679835 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL98075 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4092007 | 1.00 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121025-A2 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | Hananja Ehf (IS) | 2009-11-25 | — | — | EP | claimed |
| US-20090227568-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2009-09-10 | — | — | US | claimed |
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | IKANO THERAPEUTICS, INC. (FORMERLY KNOWN AS "INTRANASAL THERAPEUTICS, INCORPORATED") | 2008-11-06 | — | — | US | claimed |
| WO-2008089426-A2 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2008-07-24 | — | — | WO | claimed |
| EP-4691508-A1 | METHOD FOR MANUFACTURING ANTITHROMBOTIC MEDICAL DEVICE | Toyobo Co., Ltd. (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12539313-B2 | Microbial removal | CAPRETTO EHF. (IS) | 2026-02-03 | — | — | US | disclosed |
| EP-3934753-B1 | MICROBIAL REMOVAL | CAPRETTO EHF (IS) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025127042-A1 | ADHESIVE COMPOSITION AND BONDED OBJECT | 株式会社レゾナック | 2025-06-19 | — | — | WO | disclosed |
| US-12331228-B2 | Photocurable resin composition, cured product, and laminated body | THREEBOND CO., LTD. (JP) | 2025-06-17 | — | — | US | disclosed |
| WO-2025121072-A1 | METHOD FOR PRODUCING ANTI‐THROMBOGENIC MATERIAL | 東洋紡株式会社 | 2025-06-12 | — | — | WO | disclosed |
| WO-2025052775-A1 | PHOTOCURABLE RESIN COMPOSITION | 株式会社スリーボンド | 2025-03-13 | — | — | WO | disclosed |
| WO-2025018397-A1 | ADHESIVE COMPOSITION AND BONDED OBJECT | 株式会社レゾナック | 2025-01-23 | — | — | WO | disclosed |
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | IKANO THERAPEUTICS, INC. (FORMERLY KNOWN AS "INTRANASAL THERAPEUTICS, INCORPORATED") | 2008-11-06 | — | — | US | disclosed |
| WO-2008089426-A2 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2008-07-24 | — | — | WO | disclosed |
| EP-0606646-B1 | Filtermaterial, apparatus and method for removing leukocytes | ASAHI MEDICAL CO (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0538640-B1 | Acrylic copolymer elastomer and vulcanizable composition containing same | NIPPON ZEON CO (JP) | 1996-09-04 | — | — | EP | disclosed |
| EP-0606646-A1 | Filtermaterial, apparatus and method for removing leukocytes | ASAHI MEDICAL CO., LTD. (JP) | 1994-07-20 | — | — | EP | disclosed |
| US-5280080-A | Copolymerizing mixture of alkyl acrylates | NIPPON ZEON CO., LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| US-5216101-A | Heat, cold, ozone and oil resistance; useful for gaskets, hoses, conveyor belts, packing and bearing or oil seals | NIPPON ZEON CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0538640-A1 | Acrylic copolymer elastomer and vulcanizable composition containing same | NIPPON ZEON CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227568-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | MEN1 832/4885KMT2A 3911/4885TSHR 2833/4885 |
| US-12539313-B2 | Microbial removal | CUTA, MIF, PCNA | MEN1 782/4885KMT2A 2838/4885TSHR 811/4885 |
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | OPRD1, DRD2, DRD1 | MEN1 3906/4885KMT2A 2581/4885TSHR 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.